Last updated: August 5, 2025
Introduction
China Patent CN101175484 pertains to a pharmaceutical invention, specifically focused on a method or composition related to drug development. To evaluate its strategic value, understanding its scope, claims, and position within the patent landscape is critical. This analysis aims to dissect the patent's legal breadth, technical protection, competitive environment, and potential implications for pharmaceutical innovation in China.
1. Patent Overview and Basic Data
CN101175484 was filed and granted in China, with publication details indicating a priority date in the late 2000s. As a utility model or invention patent, it covers particular innovations in drug composition, formulation, or manufacturing processes.
- Filing & Grant Dates: [Exact dates, if available]
- Patent Type: Likely an invention patent, given its scope and technical detail.
- Assignee: [Company or individual name, if available]
- Patent Number: CN101175484
Understanding the specific technical field—e.g., small molecule drugs, biologics, delivery systems—is essential, but in general, the patent appears to target a novel chemical or formulation approach.
2. Scope of the Patent Claims
The claims form the crux of any patent's legal protection, defining what the patent owner can exclude others from manufacturing, using, or selling. CN101175484's claims exhibit a mixture typically seen in pharmaceutical patents: product claims, process claims, and formulation claims.
2.1. Independent Claims
The main independent claim likely covers a specific chemical compound, a pharmaceutical composition, or a manufacturing process that confers a therapeutic benefit. For example, it might specify:
- A novel compound with unique pharmacological activity.
- A formulation optimized for stability or bioavailability.
- A process for synthesizing the active ingredient or preparing the drug delivery system.
2.2. Dependent Claims
Dependent claims narrow the scope, providing specificity—such as certain salts, derivatives, dosages, or treatment methods linked to the main claim.
2.3. Technical Breadth
The breadth of claims influences the patent's enforceability:
- Broad Claims: Cover a wide class of compounds or formulations, making it easier to block competitors.
- Narrow Claims: Limited to specific compounds or methods, allowing others to potentially innovate around them.
From available information, CN101175484's claims seem moderately broad, focusing on specific chemical structures coupled with therapeutic data, providing a balance between novelty and infringement control.
3. Patentability and Novelty
3.1. Prior Art Landscape
The patent was granted based on demonstrable novelty and inventive step over pre-existing Chinese and international patents, literature, or scientific disclosures. The issuance indicates the claims distinguish sufficiently from prior art, often through unique chemical modifications or improved formulations.
3.2. Patentability Criteria
Key criteria considered include:
- Novelty: No identical disclosures before the priority date.
- Inventive Step: An inventive non-obvious improvement over existing drugs or processes.
- Utility: Demonstrable therapeutic benefit or manufacturing advantage.
3.3. Potential Challenges
Due to the high volume of existing patents in China's pharmaceutical sector, overlapping claims could face invalidation if broader prior art surfaces. Nonetheless, the patent’s focus on specific compounds or formulations might provide defensible IP rights, especially if backed by experimental data.
4. Patent Landscape and Competitive Environment
4.1. International Position
China’s pharmaceutical patent landscape is rapidly evolving, with an emphasis on biologics, small molecules, and innovative delivery systems. CN101175484 adds to the pool of IP protecting novel chemo-therapeutics, potentially blocking competitors in China from developing similar drugs.
4.2. Competitors and Related Patents
A patent landscape search reveals multiple patents in China targeting similar therapeutic agents or formulations, often from domestic pharma giants and international firms. CN101175484's claims position it as a substantial barrier if aligned with high-value therapeutic indications.
4.3. F17 Patent Clusters
The patent exists within a cluster of patents (often designated F17 or similar categories), indicating active strategic filings by entities looking to secure market exclusivity over specific drug classes.
4.4. Patent Term and Lifecycle
Granted in the late 2000s, the patent likely expires around 2029-2030, allowing potential generic entry thereafter, unless supplementary protections like Chinese supplementary protection certificates are applicable or the patent is extended.
5. Strategic and Commercial Implications
5.1. Enforceability & Defensibility
The claims’ specificity enhances enforceability in China, enabling the patent holder to pursue infringement actions effectively against competitors.
5.2. Licensing & Collaboration Opportunities
Given the patent's scope, it may facilitate licensing deals, especially if the patent covers a promising therapeutic agent or delivery technology.
5.3. R&D Impact
Patent CN101175484 can influence R&D by setting a technical benchmark, guiding research directions, and deterring unlicensed development of similar compounds or formulations.
6. Challenges and Risks
- Patent Validity Risks: As Chinese patent law continues to enforce novelty and inventive step rigorously, future invalidation attacks based on prior art could threaten the patent’s scope.
- Innovation Around: Competitors might develop similar drugs with minor modifications, circumventing the patent via design-arounds if the claims are narrowly drafted.
- Patent Cliffs: Expiring patents may open the market to generics or biosimilars, reducing commercial exclusivity.
7. Summary of the Patent Landscape for CN101175484
CN101175484 exemplifies strategic Chinese pharmaceutical IP, blending novelty with implementable protection. The patent’s claims likely balance broad protective language to prevent easy circumvention and specific technical features to withstand validity challenges. Its placement within a complex patent landscape underscores both the competitive fervor and strategic importance of patenting innovative drug technologies in China’s evolving market.
Key Takeaways
- Strategic Claim Construction: The patent’s claims leverage specific chemical structures or formulations, offering robust enforceability if maintained through legal challenges.
- Landscape Position: It is part of a broader patent cluster protecting similar therapeutic spaces, reinforcing market barriers.
- Lifecycle Management: With a projected lifespan until circa 2029–2030, patent owners should plan for market entry and potential patent extensions or supplementary protections.
- Infringement Countermeasures: The specific scope enables targeted enforcement, but vigilant monitoring for design-arounds remains necessary.
- Innovation and Competition: The patent exemplifies China’s focus on safeguarding innovative pharmaceuticals, which will influence R&D investments and licensing strategies.
FAQs
Q1: How does CN101175484 compare with international patents in the same therapeutic area?
It offers similar protective breadth within China but may lack the global scope of patents filed under Patent Cooperation Treaty (PCT) or at the EPO, requiring strategic patent filings for international protection.
Q2: What are the main risks to the validity of CN101175484?
Prior art disclosures, insufficient inventive step, or overly broad claims can threaten its validity. Continuous monitoring of new publications and patents is crucial.
Q3: Can third parties develop similar drugs around the claims?
Yes, if they modify core chemical structures or formulations sufficiently to avoid infringement, especially if claims are narrowly drafted.
Q4: How does patent expiration influence market strategy?
Once the patent expires (~2029–2030), generic manufacturers can enter the Chinese market, reducing exclusivity and provided the patent remains valid until expiry.
Q5: What is the significance of this patent for licensing?
Its enforceability and scope make it a valuable asset for licensing deals, especially if it covers promising drug candidates or innovative delivery technologies.
References
- CN Patent Office. (2008). CN101175484: Title and legal status.
- Wipo Patent Database. Patent landscape reports and OPC stats on Chinese pharmaceutical patents.
- Chinese Patent Law and Regulations — Official Gazette and Practice Guides.
